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Patients and methods: We studied 64 female SLE patients with nephritis; 32 of them had 2ry
APS (group 1) and the rest without 2ry APS (group 2). Demographic, clinical and serological data
were prospectively evaluated. Systemic lupus erythematosus disease activity index (SLEDAI) and
Systemic Lupus International Collaboration Clinics/ACR damage index (SLICC) were assessed.
Renal duplex, renal 99mTc-dimercaptosuccinic) scan (DMSA scan) and renal magnetic resonance
angiography (MRA) were all used to detect renal vascular affection.
Results: There were statistically signiﬁcant differences between the two examined groups regard-
ing damage index (p= 0.000), hypertension (p= 0.02), thrombocytopenia (p= 0.000), ﬂLDL
(p= 0.008), ﬂC3 (p= 0.01) and TMA (p= 0.04). In group 1: MR angiography detected 7 patients
with RAS: 5 patients with renal artery thrombosis that showed a signiﬁcant association with TMA
and proteinuria (p= 0.002, p= 0.004: p< 0.001, p= 0.02, respectively). Patients with RAS had
›DBP, ›s.creatinine and ›TGs (p= 0.004, p= 0.005 and p= 0.0003, respectively). Renal DMSA27626502.
m (W. Gaber).
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52 W. Gaber et al.detected 6 patients with cortical scar which showed a signiﬁcant association with TMA, proteinuria,
livedoreticularis and arthritis (p= 0.001, p= 0.01, p= 0.04 and p= 0.03, respectively) those
patients had ›DBP and ›RI (p= 0.000 and p= 0.006, respectively).
Conclusion: aPL testing should become a routine investigation in patients evaluated for RAS or
renal infarctions especially with hypertension and unexplainable deteriorating renal function. To
conﬁrm our results we propose that larger scale, multicentre studies with longer evaluation periods.
 2012 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V.
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Antiphospholipid antibodies (aPL) are a heterogeneous group
of antibodies directed against negatively-charged phospholip-
ids, phospholipid-binding proteins, and phospholipid–protein
complexes. The laboratory investigations of the update criteria
for deﬁnite antiphospholipid syndrome (APS) includes the lu-
pus anticoagulant (LAC), the anticardiolipin antibody (aCL),
and the anti-b2 glycoprotein I (b2GPI) antibody [1].
Conley and Hartman initially described the presence of lu-
pus anticoagulants in SLE patients in 1952 [2]. Subsequently,
Bowie and his colleagues described thrombosis occurring in
patients with circulating anticoagulants in a seminal paper in
1963 [3]. These observations of the association of APA with
glomerular and arterial thrombosis in SLE were extended over
the next two decades by Kant and his associates, who reported
a strong association between the presence of lupus anticoagu-
lants and the presence of glomerular thrombi in renal biopsy
specimens systematically performed in SLE patients seroposi-
tive for lupus anticoagulant [4]. While the precise origin of
APAs in SLE was unclear, their presence appears to consis-
tently correlate with the occurrence of renal thrombotic micro-
angiopathy (TMA).
In the course of the antiphospholipid syndrome (APS), the
existence of vaso-occlusive lesions capable of affecting
numerous organs is now well established. The renal involvement
attributable to APS nephropathy (APSN), corresponds to
vaso-occlusive lesions of the intrarenal vessels, associating
side-by-side with acute thromboses (with chronic arterial and
arteriolar lesions) leading tozonesof cortical ischemicatrophy [5].
The renal involvement had been associated with both pri-
mary and secondary APS. Clinical features include hyperten-
sion, renal artery stenosis, thrombotic microangiopathy and
other histological manifestations of the nephropathy (APSN),
renal vein thrombosis, APSN in the course of systemic lupus
erythematosus and renal failure. APSN is an independent risk
factor that should be included in the classiﬁcation criteria for
deﬁnite APS with characteristic clinical and histological
features [6].
2. Patients and methods
2.1. Patients
Sixty-four female SLE patients fulﬁlling the updated American
College of Rheumatology (ACR) revised criteria for the classi-
ﬁcation of SLE [7] were consecutively recruited from Rheuma-
tology department, Cairo and Fayoum University hospitals.
All of them have nephritis and thirty-two of them have second-
ary antiphospholipid syndrome. APS was diagnosed accordingto the Sapporo criteria [8]. Patients are classiﬁed into two
groups: (group 1) SLE patients with 2ry APS and (group 2)
SLE patients without APS. In (group 1) 15/32(46.9%) had
recurrent fetal loss, 4/32 (12.5%) had CVA, one patient
(3.1%) had Pulmonary artery embolism, also one patient
had transverse myelitis (3.1%) and ﬁnally 17/32(53.1%) had
venous thrombosis. Full history taking, thorough clinical
examination and laboratory investigations were done. Assess-
ment of disease activity was performed using the systemic lu-
pus erythematosus disease activity index (SLEDAI) [9],
disease damage using the Systemic Lupus International Col-
laboration Clinics/ACR damage index (SLICC/DI) [10]. Renal
biopsy was done to all patients, the specimens processed for
light microscopy and classiﬁed according to the 1982 modiﬁed
WHO morphologic classiﬁcation of lupus nephritis [11]. In-
formed consents were taken from the patients and the study
was approved by the local ethics committee.
2.2. Renal biopsy
The kidney biopsy was performed in all patients who had
either proteinuria (urinary protein concentrationP 500 mg/
dl), abnormal urinary sediment, or an elevated serum creati-
nine level. The biopsy specimens had been studied, using light
and immunoﬂuorescence microscopy, by renal pathologist
who had no knowledge of the clinical and laboratory features
of the patients. The World Health Organization (WHO) clas-
siﬁcation of lupus glomerulonephritis [11] and the WHO activ-
ity and chronicity index scores [12] were reevaluated.
The immunoﬂuorescence microscopy ﬁndings as described
in the initial reports of the kidney biopsies were accepted.
APS nephropathy was diagnosed when at least 1 of the follow-
ing lesions was detected: thrombotic microangiopathy (TMA),
characterized by the presence of ﬁbrin thrombi in arterioles
and/or glomeruli (acute lesion), or myoﬁbroblastic intimal cel-
lular proliferation leading to intimal thickening of interlobular
arteries, organized thrombi with or without recanalization, ﬁ-
brous arterial and arteriolar occlusion, and subcapsular zone
with FCA (chronic lesions) [5] .
2.3. Laboratory investigations
Antinuclear and anti-DNA antibodies, C3, and C4 were as-
sessed according to standard methods. Determination of IgG
and IgM antibodies to aCL was performed with an enzyme-
linked immunosorbent assay [13], Cardiolipin (50 lg/ml) in
ethanol (Sigma, St. Louis, MO) was used as antigen on poly-
styrene micro titer plates (Nunc, Naperville, IL), which were
left to dry overnight at 4 C. After washing with phosphate
buffered saline, the nonspeciﬁc binding sites were blocked by
Table 1 DMSA scan interpretation criteria are according to
Patel and his associates [19].
DMSA
Normal ﬁndings
 Normal contour: smooth and continuous without indentations
 Homogeneous parenchymal uptake in all regions of both kidneys
 Normal size and shape of both kidneys
Inﬂammation
 Slightly bulging or normal contour
 Single or multiple, local or diffuse areas of decreased activity
in parenchyma
which are diffuse or, rarely, spheric, in at least 2 projections
 Mild to severe degree of photopenia or, rarely, complete absence
of activity
 No volume loss
Scarring
 Diffuse or sharp indentation in contour with thinning of cortex
 Any shape defects with loss of renal volume
 Photopenia (usually severe) or absent activity
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sayed by activated thromboplastin time [14]. The detection of
LAC in medium or high titers of aCL at least 2 times, 6 weeks
apart, before or at the time of kidney biopsy, was required [8].
2.4. Exclusion criteria
The criteria for exclusion from the study were other potential
causes for renal microangiopathy, such as systemic sclerosis,
malignant hypertension, thrombotic thrombocytopenic pur-
pura, hemolytic uremic syndrome, postpartum renal failure,
preeclampsia, diabetic nephropathy, chemotherapy, or cyclo-
sporine therapy.
2.5. Radiological examination
2.5.1. Renal ultrasound and color Doppler examination
Renal Doppler US was performed successfully in each study
patient and was accomplished in 15 min or less. In each pa-
tient, both kidneys were examined with real-time US, per-
formed with a 3.5–5 MHz transducer.
Assessment of the size, parenchymal thickness and cortical
contour of both kidneys were performed. The echogenicity and
cortico-medullary differentiation of the kidneys were assessed.
The intra-renal arteries were examined with pulsed Doppler
US at the same respective scanning frequencies. Multiple
Doppler signal tracings and a standard gray-scale examination
of the kidney were recorded. Doppler signals were, in general,
obtained from arcuate arteries at the cortico-medullary junc-
tion, interlobar arteries along the border of medullary pyra-
mids, or both. The Doppler waveforms were made on the
lowest pulse repetition frequency possible without aliasing.
This maximized the size of the Doppler spectrum and de-
creased the percentage of error in the measurements. In addi-
tion, the lowest possible wall ﬁlter for each US scanner was
used. Doppler sample width was set at 2–5 mm. The resistive
index (RI) ([peak systolic frequency shift-minimum diastolic
frequency shift]/peak systolic frequency shift) was calculated.
The RI for each kidney was calculated as an average value ob-
tained from three to ﬁve waveforms recorded in three different
regions of the kidney. An RI of P0.70 was considered
abnormal.
The main renal arteries were also examined for focal areas of
stenosis or luminal reduction. Multiple Doppler tracings were
recorded for elevated peak systolic velocity (PSV) or RI [15].
2.5.2. Magnetic resonance angiography of both renal arteries
All MR angiography examinations were performed by using a
1.5-T whole-body MR system (Philips Medical Systems) with a
gradient strength of 30 mT/m and a slew rate of 150 (mT-m-1)/
msec. A four-element phased-array body coil was used for
signal reception.
Coronal single-shot fast SE or half-Fourier single-shot tur-
bo SE imaging with the following parameters: repetition time
(msec)/echo time (msec),1/120; ﬂip angle. 90; and acquisition
time, 20 s (breath hold). This heavily T2-weighted sequence
provides an overview of the upper abdominal anatomy, renal
parenchyma and collecting system and serves as a localizing se-
quence for planning other sequences in the protocol.
Furthermore, a two-dimensional non enhanced phase-
contrast (PC) sequence (5/3 and 50 ﬂip angle) was performedfollowed by standard time of ﬂight (TOP) sequence (4.2/1.8
and 70 ﬂip angle) [16].
2.5.3. 99mTc-DMSA (99mTc-dimercaptosuccinic) scan
acquisition and interpretation
DMSA scan was performed using a standard protocol.
Injected activities were the recommended adult dose in the
range of 3–5 mCi (110 MBq–185 MBq). Data were acquired
on a dual-head, large-ﬁeld-of-view gamma camera (Axis-
Phillips-Marconi medical systems) equipped with low-energy,
high-resolution parallel collimators in a 256 · 256 matrix.
Planar posterior, anterior, left posterior, and right posterior
oblique views were obtained 3–4 h after intravenous injection
of 99mTc-DMSA (Renocis; CIS Bio International, Gif-sur-Yv-
ette, France). Acquisitions were continued to a total of
750 kilocounts or 300 s (5 min). No sedation was used [17,18].
Two experienced physicians unaware of the patient’s clini-
cal and radiological data interpreted the ﬁndings according
to the criteria of Patel and his colleagues as shown in (Table
1) and discrepancies were resolved by consensus. At the time
of diagnosis, DMSA ﬁndings were judged to be abnormal
when the criteria for scarring were satisﬁed. Defects located
centrally over the pelvicalyceal system were not considered
abnormal [19].
Statistical analysis: The data were coded and entered
using the statistical package SPSS version 15. The data were
summarized using descriptive statistics: mean, standard devi-
ation, minimal and maximum values for quantitative vari-
ables and number and percentage for qualitative values.
Statistical differences between groups were tested using Chi
Square test for qualitative variables, independent sample t
test for quantitative normally distributed variables while
Nonparametric Mann Whitney test was used for quantitative
variables which are not normally distributed. P-values less
than or equal to 0.05 were considered statistically signiﬁcant
[20].
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3.1. Data of all studied SLE patients (with and without 2ry
APS)
There were 64 SLE patients with nephritis, 32/64 (50%) of
them had 2ry APS (group 1) and another 32/64 (50%) matched
SLE patients with nephritis, but with out 2ry APS as a control
group (group 2). The demographic and clinical features are
presented in Table 2, laboratory parameters and renal biopsy
of the two groups are presented in Table 3 and medication re-
ceived are presented in Table 4.
3.2. Results of magnetic resonance angiography of both renal
arteries
MR angiography had detected 7(21.9%) patients with RAS in
(group1) and on comparing the two groups it showed a statis-
tically highly signiﬁcant difference (p= 0.005). RAS appeared
as smooth, well-deﬁned and noncritical stenosis distal to the
renal artery ostium as shown in (Fig. 1). Patients with RAS
showed a signiﬁcant association with TMA and proteinuria
(p= 0.002 and p= 0.004, respectively). Patients with RAS
had higher DBP, s.creatinine, TGs and renal RI than those
without RAS (p= 0.004, p= 0.005, p= 0.003 and
p= 0.008, respectively).
MR angiography also detected 5(15.6%) patients with re-
nal artery thrombosis in (group1) as shown in (Fig. 1) that
showed a statistically signiﬁcant difference (p0.02) on com-
paring the two groups. Patients with renal artery thrombosis
showed a signiﬁcant association with TMA, proteinuria and
arthritis (p< 0.001, p= 0.02 and p= 0.03, respectively). Pa-
tients with renal artery thrombosis had higher SBP, DBP,
thrombocytopenia, s.creatinine, TGs and renal RITable 2 Descriptive data of the studied patients.
Demographic features (mean ± SD) Group 1 (SLE with 2ry APS
Age (years) 29.3 ±7.3
Disease duration (years) 4.9 ±3.01
Disease Activity & Damage index
SLEDAI 19.0 ±9.04
SLICC 1.4 ±1.04
Clinical Manifestations Number (%)
Constitutional symptoms 4 12.5%
Mucocutaneous 16 50%
Arthritis 8 25%
Neuropsychiatric 8 25%
Cardiovascular 2 6.3%
Pulmonary hypertension 2 6.3%
Vasculitis 6 18.8%
Hypertension 17 53.1%
Miscarriage 15 46.9%
Venous thrombosis 17 53.1%
Arterial thrombosis 4 12.5%
Renal activity index 18 56.3%
Renal chronicity index 17 53.1%
SLEDAI: Systemic lupus erythematosus disease activity index. SLICC: S
* is signiﬁcantly different at p< 0.05.
** is signiﬁcantly different at p< 0.001.(p= 0.004, p= 0.000, p= 0.04, p= 0.0004, p= 0.009 and
p= 0.04, respectively).
3.3. Results of 99mTc-DMSA scan
Renal DMSA scan had detected 6(18.8%) patients with corti-
cal scar as shown in (Fig. 2) which showed a statistically signif-
icant difference (p= 0.02) on comparing the two groups. It
showed also a signiﬁcant association with TMA (p= 0.001)
and signiﬁcant association with proteinuria, livedoreticularis
and arthritis (p= 0.01, p= 0.04 and p= 0.03, respectively).
Patients with cortical scar had higher DBP and renal RI
(p= 0.000 and p= 0.006, respectively).
3.4. Results of renal ultrasound and color Doppler examination
Renal Duplex detected 12(37.5%) patients with increased ech-
ogenecity (nephropathy) which showed a signiﬁcant associa-
tion with alopecia, fever, TMA, proteinuria, casturia and
mucosal ulcers (p< 0.001, p= 0.02, p= 0.005, p= 0.004,
p= 0.02 and p= 0.01, respectively). Patients with › eccho-
genecity had higher DBP, renal RI and ESR (p= 0.02,
p= 0.000 and p= 0.01, respectively).
Decreased renal size had been detected by renal Duplex in
one patient only (3.1%) and showed a signiﬁcant association
with TMA (p= 0.02).
4. Discussion
The antiphospholipid antibody syndrome (APS) described a
clinical entity with recurrent thrombosis, fetal loss, thrombo-
cytopenia in the presence of lupus anticoagulant and/or anti-
bodies to cardiolipin. These antibodies may be associated
with connective tissue diseases such as systemic lupus erythe-) Group 2 (SLE without 2ry APS) P value
25.9 ±7.8 0.08
3.1 ±2.2 0.02*
25.03 ±7.7 0.003**
0.2 ±0.4 0.000**
14 43.8% 0.005**
32 100% 0.001**
19 59.4% 0.02*
7 21.9% 0.6
0 0% 0.2
2 6.3% 0.2
15 46.9% 0.02*
11 34.4% 0.02*
0 0% 0.000**
0 0% 0.000**
0 0% 0.04*
26 81.3% 0.03*
13 40.6% 0.3
ystemic Lupus International Collaborating Clinics.
Table 3 Laboratory investigations and renal biopsy of the two groups.
Laboratory investigations Group 1(SLE nephritis with 2ry APS) Group 2(SLE nephritis without 2ry APS) P value
ESR 1st hour (mmHg) 37.3 ±18.5 45.8 ±19.4 0.02*
Hemoglobin (g%) 10.4 ±1.3 10.6 ±1.9 0.6
WBCs (·103/mm3) 4.1 ±0.9 4.6 ±1.1 0.09
Platelets (·103/mm3) 118.9 ±29.7 209.9 ±50.4 0.000**
AST (U/L) 25.5 ±8.7 21.9 ±8.7 0.1
ALT (U/L) 23.3 ±9.8 23.7 ±8.5 0.8
S.Albumin (g/dl) 3.3 ±0.6 3.1 ±0.6 0.3
S.Creatinine (mg/dl) 1.03 ±0.6 0.9 ±0.3 0.3
Proteinuria No (%) 25 78.1% 29 90.6% 0.5
LDL mg/dl 147.9 ±32 171.8 ±37 0.008**
HDL mg/dl 54.2 ±16.3 41.8 ±11.9 0.001**
Cholesterol mg/dl 193.3 ±61.5 208.3 ±80.6 0.5
Triglycerides mg/dl 157.8 ±60.2 197.3 ±88.9 0.1
Consumed C3 No (%) 10 31.3% 22 68.8% 0.01*
Consumed C4 No (%) 15 46.9% 17 53.1% 0.3
LAC No (%) 25 78.1% 1 3.1% 0.000**
ACL No (%) 31 96.9% 0 0% 0.000**
a-PTT prolongation No (%) 25 78.1% 1 3.1% 0.000**
Anti-dsDNA No (%) 14 43.8% 22 68.8% 0.003**
TMA No (%) 6 18.8% 0 0% 0.04*
ESR: Erythrocyte sedimentation rate, AST: Aspartate transaminase, ALT: Alanine transaminase, ACL: anti-cardiolipin, LAC: lupus antico-
agulant, a-PTT: activated partial thromboplastin time ANA: antinuclear antibodies TMA: Thrombotic microangiopathy.
* is signiﬁcantly different at p< 0.05.
** is signiﬁcantly different at p< 0.001.
Table 4 Medications received by the study groups.
Medications Group 1(SLE with 2ry APS) Group 2(SLE without 2ry APS) P value
Cumulative steroid dose by gm(mean ± SD) 33.1 ±25.5 22.9 ±12 0.03*
Cumulative HQN dose by gm(mean ± SD) 440.4 ±286.6 378.6 ±204.3 0.8
Cumulative azathioprine dose by gm(mean ± SD) 94.7 ±97.2 70.7 ±58.5 0.7
Cumulative cyclophosphamide dose by gm(mean ± SD) 3.5 ±4.03 2.9 ±4.1 0.6
Methotrexate No (%) 7 21.9% 6 18.8% 0.8
Marivane No (%) 32 100% 0 0% <0.001**
Baby aspirin No (%) 26 81.3% 0 0% <0.001**
Mycophenolate mofetil No (%) 4 12.5% 7 21.9% 0.3
* is signiﬁcantly different at p< 0.05.
** is signiﬁcantly different at p< 0.001.
Figure 2 DMSA scan shows small cortical renal infarction
(sharp indentation) at upper pole of left kidney (black arrow).
Figure 1 Magnetic resonance angiography shows left renal
artery stenosis and thrombosis distal to the renal artery ostium
(white arrow).
Comparative study of kidney affection in SLE patients with and without antiphospholipid syndrome 55matosus (secondary APS) or be found in isolation (primary
APS). Renal syndromes increasingly being reported in
association with these antibodies which include thrombotic
56 W. Gaber et al.microangiopathy, renal vein thrombosis and renal infarction,
renal artery stenosis [21].
In the current study we had found that aPL antibodies in
SLE patients with renal involvement represent a strong risk
factor for the RAS and the thrombotic events within the
kidney.
In the present study we had examined 64 SLE patients with
nephritis, 50% of them had 2ry APS, to detect renal manifes-
tations caused by aPL antibodies by different means as renal
Duplex, renal MRA and renal DMSA scan.
MR angiography detected 7/32(21.9%) patients with RAS,
who showed highly signiﬁcant association with hypertension
and this can be explained by the fact that RAS impairs renal
perfusion, leading to renal ischemia, which in turn activates
the rennin–angiotensin axis. The production of angiotensin
II leads to sodium retention, vasoconstriction and increased
sympathetic activity. It also has detrimental effects on nitric
oxide production and endothelial function. Renovascular
hypertension is the result of this process [22,23].
TMA were present in 6/32(18.8%) patients with 2ry APS
and had a highly signiﬁcant association with renal infarctions
that had been detected by DMSA scan as micro thrombi could
mechanically obstruct glomerular capillaries, diminishing the
blood supply to glomeruli and renal tubules, thereby causing
chronic hypoxic/ischemic injuries to the affected glomeruli
and tubules. This would in turn decrease the glomerular ﬁltra-
tion rate leading to the loss of nephrons and impaired renal
function. Clinical studies had indicated that lupus nephritis
(LN) patients with glomerular micro thrombi (GMT) had
more severe renal tissue injury, poorer response to general
treatment and worse renal outcome than patients without
GMT [5]. Consistent with these ﬁndings, we had demonstrated
in the present study that LN patients with GMT had higher
damage index (SLICC) than those without. The level of serum
creatinine, and proteinuria, as well as the frequency of systemic
hypertension, were all signiﬁcantly greater in patients with
GMT. Taken together, GMT may be an important cause of re-
nal injury and renal dysfunction in a subset of patients with
LN and this coincides with the results of Hui Zheng and his
colleagues [24] and also with those of Imad Uthman and
Munther Khamashta who documented that. The development
of aPL nephropathy in the context of SLE nephritis increases
the risk of a poor renal outcome [25].
Antiphospholipid syndrome nephropathy had been de-
scribed as a distinct entity found in one third of lupus nephritis
patients but independent of the lupus lesions [26]. In the pres-
ent study APS nephropathy had been detected in (21.9%) of
our patients which was a little bit lower than the described per-
centage and this can be explained by the lower number of SLE
patients with 2ry APS taken in the present study, which should
be increased in future studies.
APS nephropathy was strongly associated with both aCL
and LA, suggesting that APL plays a direct role in the devel-
opment of APS nephropathy [27] and this also coincides with
the results of the present study.
Low density lipoproteins were signiﬁcantly lower in cases
with SLE and 2ry APS, this can be explained by being con-
sumed. This was previously explained by Hasunuma Y. and
his colleagues who documented at a molecular level, that anti-
cardiolipin antibodies (aCL) had been shown to have athero-
genic properties. For example, aCL can cross react withoxidized low density lipoproteins (ox-LDL), and may enhance
the in vitro uptake of ox-LDL by monocytes [28].
Sangle and his colleagues had demonstrated the presence of
RAS in (26%) of (77) patients with aPL and uncontrolled
blood pressure (60 with SLE and APS, 11 with primary
APS, 6 with aPL only). They observed two possible patterns
regarding stenotic artery lesions. The most represented pattern
was smooth, well-deﬁned and noncritical stenosis distal to the
renal artery ostium, these ﬁndings are different from athero-
sclerotic and ﬁbromuscular dysplasia-related lesions. Indeed,
the other described pattern seems to be similar to atheroscle-
rotic lesions and had been found in the proximal region to
the ostium of the renal artery, sometimes involving the aorta
[29]. This coincides with the results in the present study as
we found RAS in (21.9%) of patients and they appeared as
smooth, well-deﬁned and noncritical stenosis distal to the renal
artery ostium, but we did not ﬁnd proximal lesions.
5. Conclusion
Previously, it was said that, in SLE patients with aPL it is cru-
cial to distinguish between renal failure due to SLE nephritis
(immune-complex disease) from that due to APS (glomerular
thrombosis). This distinction, which can only be accomplished
by kidney biopsy, is critical as the treatment for each syndrome
is different. Aggressive SLE nephritis requires cytotoxic ther-
apy, whereas APS nephropathy beneﬁts from anticoagulation.
But now we can add that renal MR angiography and renal
DMSA can differentiate between the two conditions, which
are less aggressive and safer maneuvers than renal biopsy espe-
cially in patients with thrombocytopenia accompanying APS.
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